Holdings
AdvisorShares Psychedelics ETF
As of Jun 30, 2026, AdvisorShares Psychedelics ETF reported 24 positions worth US$36.9M. Largest: Definium Therapeutics, Inc., Ataibeckley Inc. and Relmada Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | 121K | US$5.71M | +30,080 | Jun 30, 2026 |
| Ataibeckley Inc. | 883K | US$4.65M | +315K | Jun 30, 2026 |
| Relmada Therapeutics, Inc. | 439K | US$3.04M | +143K | Jun 30, 2026 |
| Nrx Pharmaceuticals, Inc. | 659K | US$2.7M | +239K | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 11,553 | US$1.95M | +4,383 | Jun 30, 2026 |
| Cybin, Inc. | 293K | US$1.93M | +97,107 | Jun 30, 2026 |
| Gh Research Plc | 71,267 | US$1.92M | +4,233 | Jun 30, 2026 |
| Alkermes Plc | 36,438 | US$1.91M | +10,069 | Jun 30, 2026 |
| Alto Neuroscience, Inc. | 70,748 | US$1.87M | +29,725 | Jun 30, 2026 |
| Abbvie Inc. | 7,318 | US$1.84M | +3,153 | Jun 30, 2026 |